Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Net Cash Flow: 2014-2025

Historic Net Cash Flow for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $47.9 million.

  • Ascendis Pharma A's Net Cash Flow fell 88.26% to $47.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.7 million, marking a year-over-year decrease of 140.40%. This contributed to the annual value of $156.5 million for FY2024, which is 412.20% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Net Cash Flow is $47.9 million, which was up 1,000.30% from -$5.3 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Net Cash Flow peaked at $407.7 million during Q3 2024, and registered a low of -$295.0 million during Q4 2021.
  • In the last 3 years, Ascendis Pharma A's Net Cash Flow had a median value of -$34.8 million in 2025 and averaged $10.9 million.
  • Within the past 5 years, the most significant YoY rise in Ascendis Pharma A's Net Cash Flow was 816.62% (2024), while the steepest drop was 222.30% (2024).
  • Over the past 5 years, Ascendis Pharma A's Net Cash Flow (Quarterly) stood at -$295.0 million in 2021, then spiked by 51.19% to -$144.0 million in 2022, then spiked by 68.71% to -$45.1 million in 2023, then tumbled by 107.47% to -$93.5 million in 2024, then slumped by 88.26% to $47.9 million in 2025.
  • Its Net Cash Flow stands at $47.9 million for Q3 2025, versus -$5.3 million for Q2 2025 and -$34.8 million for Q1 2025.